Florida Cancer Specialists | Association Partnerships

Latest from Florida Cancer Specialists

FCS Names Shekeab Jauhari as Principal Investigator for their New Drug Development Unit

December 26, 2019

Shekeab Jauhari, MD, a medical oncologist/hematologist, has been named principal investigator at the Florida Cancer Specialists & Research Institute, and he will lead phase I clinical trials at the FCS Drug Development Unit in Lake Mary, Florida, at the Sarah Cannon Research Institute, which is the newest unit in the FCS that is set to open in January 2020.

Discussing the Benefits of Trilaciclib Plus Topotecan for Treatment of Extensive-stage SCLC

August 27, 2019

Lowell L. Hart, MD, FACP, scientific director of clinical research, Florida Cancer Specialists, and associate professor of medicine, Wake Forest University School of Medicine, discusses the effect of CDK4/6 inhibitor, trilaciclib on myelosuppression in patients with previously treated extensive-stage small cell lung cancer receiving topotecan. Hart presented the phase II results from the blinded, multicenter study during the 2019 ASCO Annual Meeting.

FCS and Cigna Create New Initiative Focused on Better Patient Experience

August 23, 2019

Florida Cancer Specialists & Research Institute has announced an oncology-focused initiative with Cigna as a part of the Cigna Collaborative Care. The Cigna Oncology Focus program's main goal is to provide quality care and contain costs for people with cancer. It also uses incentives to encourage healthcare professionals to improve affordability, as well as patients’ health and overall experience.